PARIS Feb 28 French drugmaker Ipsen
returned to net profit in 2013, lifted by sales of specialty
care drugs, and aims to preserve its margin as it prepares a
U.S. launch of its Somatuline treatment against neuroendocrine
Full-year operating profit jumped 63 percent to 191 million
euros ($261 million), lifting the operating margin to 17 percent
from 16.3 percent in 2012.
Ipsen said on Friday it would maintain its operating margin
between 16 and 17 percent this year. It aims to file Somatuline
for approval in the United States in the first half.
Ipsen said it expected sales of specialty care drugs to rise
4 to 6 percent this year, while revenue from products prescribed
by family doctors would be stable or fall 2 percent.
Ipsen posted net profit of 153.1 million euros after a loss
of 27.5 million in 2012, when it exited the haemophilia market.
It is paying a stable dividend of 0.80 euros per share.
Shares in Ipsen are down more than 9 percent so far this
year after a 51 percent jump in 2013. They closed at 31.19 euros
on Thursday, giving the company a market capitalisation of about
2.6 billion euros.